ADMA Biologics Surges 27% on a Blowout Quarter — But Can Its Star Drug Carry the Whole Company?

Shares vaulted 27.5% after hours as ADMA Biologics reported third-quarter results that snapped a streak of disappointments, raising an urgent question: whether its specialty immunoglobulin therapy can single-handedly offset a crumbling standard-drug business and justify the stock's renewed optimism.

The Quarter That Flipped the Narrative. Total revenue hit $141.1 million, up 13% sequentially and 5% year over year, while adjusted EBITDA grew 25% quarter over quarter to $77.3 million.

Wall Street had expected roughly $139.8 million in revenue and $0.19 earnings per share ; ADMA delivered $0.22 in GAAP EPS, a 47% year-over-year jump. That beat matters enormously for a company that missed estimates in both Q1 and Q2, when it posted just $0.16 EPS against a $0.17 consensus.

One Drug Is Doing All the Heavy Lifting. Asceniv — a specialty immune therapy for patients with complex, hard-to-treat immunodeficiency — generated $124.7 million, up 31% year over year and 21% sequentially, driven by more doctors prescribing it and more new patients starting treatment. That one product now represents 88% of total revenue. Meanwhile, Bivigam, the company's standard immunoglobulin drug, slid to just $15.4 million from $19.4 million the prior quarter amid fierce competitor discounting. The concentration risk is stark: if Asceniv growth stalls, ADMA has almost no fallback.

Better Manufacturing Is Fattening Profits. Gross margin reached 71%, up from 69% last quarter and just 56% a year ago, reflecting a more profitable product mix and higher yields from upgraded manufacturing. That 15-percentage-point annual jump means each dollar of Asceniv revenue drops far more profit to the bottom line — gross profit reached $99.9 million, up from $75.6 million a year earlier.

Full-Year Guidance Tells a Sobering Backstory. Management reiterated full-year revenue of at least $530 million and raised adjusted net income guidance to at least $180 million. But context matters: back in January, ADMA had guided for over $635 million in 2026 revenue before slashing that target in May, citing aggressive pricing and oversupply in the standard immunoglobulin market. The stock remains well below where it traded before that guidance cut. Even after tonight's pop, investors are essentially betting that Asceniv's trajectory can eventually close a $100 million-plus revenue gap that Bivigam left behind — a bet that hinges on continued physician adoption in a niche patient population.